Comparative Efficacy and Safety of Intermediate-acting, Long-acting and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis
[sidebar] Commissioned and funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
- Our findings can inform patients with T1DM and their health care providers in developing tailored insulin treatment regimens
- The results of this study were included in a World Health Organization Essential Medicines application and will inform clinical practice guidelines worldwide
Related Projects:
- Type 2 diabetes mellitus: treatments
- Type 1 diabetes mellitus: long-acting versus intermediate-acting insulin
Category : KS Projects
Date : 29 Oct 2019